Chimeric canine anti-CD20 antibody
The disclosure relates to caninized chimeric anti-CD20 antibodies to the canine protein CD20 and methods of use to treat certain disorders such as non-Hoiodgkins B-cell lymphoma in dogs.
1. A method of detecting CD20 in a sample: said method comprising:
a) contacting a sample with an antibody selective for canine CD20; wherein said antibody comprises:
a light chain variable region (LCVR) whose amino acid sequence is that given in SEQ ID NO: 12, and a heavy chain variable region (HCVR) whose amino acid sequence is that given in SEQ ID NO: 3; or
a light chain variable region (LCVR) comprising a first complementary determining region (LCDR1) whose amino acid sequence is that given in SEQ ID NO: 14, a second CDR (LCDR2) whose amino acid sequence is that given in SEQ ID NO: 16, a third CDR (LCDR3) whose amino acid sequence is that given in SEQ ID NO: 18, and a joining (J) region whose amino acid sequence is that given in SEQ ID NO: 19; and a heavy chain variable region (HCVR) comprising a first CDR (HCDR1) whose amino acid sequence is that given in SEQ ID NO: 5, a second CDR (HCDR2) whose amino acid sequence is that given in SEQ ID NO: 7, and a third CDR (HCDR3) whose amino acid sequence is that given in SEQ ID NO: 9; and wherein the antibody specifically binds to canine CD20; and
b) washing the sample, and
c) detecting the antibody selective for canine CD20.
2. The method according to claim 1 , wherein the sample comprises canine lymphoma tissue.
3. The method according to claim 2 , wherein the sample comprises a tissue cryosection.
4. The method according to claim 1 , wherein the method further comprises contacting the sample with a second antibody; wherein the second antibody is selective for the antibody selective for canine CD20.
5. The method according to claim 1 , wherein the antibody selective for canine CD20 is labeled.
6. A kit, comprising a pharmaceutical composition, comprising an antibody which specifically binds to canine CD20, with one or more pharmaceutically acceptable carriers, diluents, or excipients and a chemotherapeutic agent;
wherein the antibody which specifically binds to canine CD20 comprises a light chain variable region (LCVR) comprising a LCDR1 of SEQ ID NO: 14, a LCDR2 of SEQ ID NO: 16, a LCDR3 of SEQ ID NO: 18, and a J region of SEQ ID NO: 19; and a heavy chain variable region (HCVR) comprising a HCDR1 of SEQ ID NO: 5, a HCDR2 of SEQ ID NO: 7, and a HCDR3 of SEQ ID NO: 9.
7. A kit, comprising a pharmaceutical composition, comprising an antibody which specifically binds to canine CD20, with one or more pharmaceutically acceptable carriers, diluents, or excipients and a chemotherapeutic agent;
wherein the antibody which specifically binds to canine CD20 comprises a light chain variable region (LCVR) whose amino acid sequence is that given in SEQ ID NO: 12, and a heavy chain variable region (HCVR) whose amino acid sequence is that given in SEQ ID NO: 3.